Skip to content

Sublingual misoprostol and PPH

Sublingual misoprostol versus intramuscular oxytocin in the active management of the third stage of labour: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202504725860997
Enrollment
102
Registered
2025-04-09
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

Dr. Okoiseh
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women at term, in labour having singleton pregnancy with cephalic presentation, scheduled to undergo vaginal delivery 2. Pregnant women with packed cell volume of 30% and above 3. Pregnant women who voluntarily consented to participate in the study

Exclusion criteria

Exclusion criteria: 1. Multiple gestation 2. Pregnancy with co-existing uterine fibroids 3. Women undergoing instrumental delivery 4. Women with polyhydramnios 5. Pregnant women with coagulation disorders 6. Maternal medical conditions in pregnancy like pre-eclampsia, eclampsia 7. Women with hypersensitivity to the drugs to be administered ( oxytocin, misoprostol), or pregnant women with febrile illness 8. Women with traumatic PPH such as those with cervical laceration and perineal laceration 9. Grand multiparous women 10. Women with antepartum Haemorrhage 11. Women with scarred uteri ( From previous myomectomy or caesarean section)

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be the incidence of primary postpartum hemorrhage (PPH).

Secondary

MeasureTime frame
Secondary outcomes measure will include, mean postpartum blood loss, duration of third stage of labour, side effects of the drugs, need for additional uterotonics, blood transfusion and postpartum haemoglobin

Countries

Nigeria

Contacts

Public ContactCollins Chikereze

Resident Doctor

collo10000@gmail.com+2347039491761

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026